Therapies targeting hormonal and endocrine alterations: Since insulin-like growth factor-1 (IGF-1) levels are significantly reduced in patients with cirrhosis—a phenomenon attributed to modifications in growth hormone (GH) receptor expression in the liver [132]—replacement or modulation of IGF-1 could serve as a therapeutic intervention targeting hormonal imbalance. Here, IGF1 is linked to Cirrhosis.